Skip to main content
. Author manuscript; available in PMC: 2014 Sep 22.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007771. doi: 10.1002/14651858.CD007771.pub2

Table 2. Summary of outcomes: adverse events and withdrawals.

Study ID Intervention AnyAE Serious AE All cause withdrawal LoE withdrawal AE withdrawal
Brohult 1973

  1. 100 000 IU calciferol/day, n = 24

  2. Placebo, n = 25

 no data no data

  1. 4/24

  2. 6/25

 Worsening of disease:

  1. 3/24

  2. 6/25

 Death:

  1. 1/24 (PE)

  2. 0/25
Di Munno 1989

  1. 35 μg/day 25-(OH)D for 25 day/month, n = 12

  2. Placebo, n = 12


All had 500 mg calcium and 6-methylprednisolone

  1. 0/12

  2. 0/12

  1. 0/12

  2. 0/12

 no data no data no data
Yamauchi 1989

  1. 1 μg/day alfacalcidol, n = 59

  2. 2 μg/day alfacalcidol, n = 55

  3. Placebo, n = 57

  1. 1/59

  2. 2/55

  3. 3/57

  1. 1/59

  2. 0/55

  3. 0/57

  1. 14/59

  2. 9/55

  3. 8/57

  1. 1/59

  2. 0/55

  3. 0/57

  1. 1/59

  2. 2/55

  3. 3/57
Warner 2008

  1. 50 000 IU ergocalciferol/week, n = 25

  2. Placebo, n = 25

 no data no data

  1. 3/25

  2. 5/25

 no data

  1. 0/25

  2. 0/25

AE - adverse event; LoE - lack of efficacy; PE - pulmonary embolus

Yamauchi 1989 reported that there were two participants with adverse events in the placebo groups. However, because there were three adverse event withdrawals in those group the number of participants with adverse events is given as three in the above table.